AC Immune’s Parkinson’s Vaccine Conceals Alpha in a Market That Remains Unresponsive

AC Immune: A Company at a Crossroads

AC Immune finds itself in a challenging position, with its recent performance reflecting more disappointment than promise. As of March 20, 2026, the company’s shares ended the day at $2.85, a 3.39% drop and hovering just above its 52-week low of $2.75. Investor enthusiasm is clearly lacking, as seen in the company’s financials: a net loss of CHF 70.45 million for 2025—a substantial increase from the previous year—while revenue dwindled to CHF 3.57 million. Even significant clinical developments have failed to spark a rally in the stock.

In December 2025, AC Immune revealed encouraging interim Phase 2 results for its Parkinson’s vaccine, ACI-7104. The findings suggested, for the first time, that targeting alpha-synuclein with an active immunotherapy could slow the progression of Parkinson’s disease. The vaccine demonstrated a strong safety profile and promising biomarker improvements. Yet, despite these advances, the stock remained near its lows, indicating that investor sentiment remains subdued and the market has largely moved on.

This disconnect sets the stage for a high-stakes scenario. AC Immune is burning through cash, but it holds a potentially transformative asset that could reshape the treatment landscape for neurodegenerative diseases. Should the company achieve a major regulatory milestone, release pivotal clinical data, or benefit from a broader industry breakthrough, its undervalued stock could quickly become a focal point. With the market largely ignoring the positive signals so far, the potential for a dramatic turnaround remains—if the right catalyst emerges.

Upcoming Catalysts: What Could Change the Narrative?

Market sentiment can shift rapidly, especially when clear milestones are on the horizon. For AC Immune, the coming quarters are packed with events that could reignite investor interest. These aren’t routine updates—they are pivotal moments that could drive renewed attention and a potential revaluation if the outcomes are favorable.

• Alzheimer’s Program Milestone: Interim results from the AD3 cohort of the Phase 2 ABATE trial for ACI-24 are expected in the first half of 2026. As this program is already partnered with a major pharmaceutical company, positive data could revitalize the company’s entire development pipeline and attract new investment.
• Parkinson’s Vaccine Data: The full 24-month results from Part 1 of the Phase 2 VacSYn trial for ACI-7104 are anticipated in the third quarter of 2026. This will provide the most comprehensive assessment yet of the vaccine’s long-term impact on disease progression. A strong, positive outcome would be a major validation of AC Immune’s scientific approach.

Importantly, AC Immune has the financial resources to pursue these milestones. As of December 31, 2025, the company reported CHF 91.4 million in cash, which management believes will support operations through the end of the third quarter of 2027. This runway provides a buffer against near-term financial pressures and ensures the company can see these critical trials through to completion.

The next several months will determine whether the market’s current indifference is justified or simply a temporary oversight. Each upcoming milestone has the potential to spark renewed interest and reposition AC Immune as a leader in neurodegenerative disease innovation.

Market Sentiment: A Gap Between Promise and Perception

There is a clear divide between AC Immune’s scientific potential and its current market valuation. On one hand, the company has a promising pipeline and analysts see room for growth. On the other, the stock remains depressed, revenue has collapsed, and investor enthusiasm is lacking. This disconnect is at the heart of the investment case.

Analyst opinions are mixed. The consensus is a "Hold" rating, with an average price target of $9.00—significantly higher than the current price of $2.85. This target reflects optimism that clinical progress, especially with the Parkinson’s vaccine, will eventually be recognized by the market. However, recommendations are split: one "Sell," one "Hold," and three "Buy" ratings, highlighting the uncertainty that often surrounds clinical-stage biotech companies.

The company’s financials reinforce the challenges. Revenue for 2025 dropped to CHF 3.57 million, a steep decline from the previous year. This is not a story of slow growth, but rather a business model that has yet to achieve meaningful commercial success. The company’s value is now tied almost entirely to the success of its clinical programs. When the interim Parkinson’s vaccine data was released in December 2025, the stock barely moved, underscoring the lack of market excitement.

Ultimately, analyst optimism has yet to translate into increased investor interest. The stock’s persistent position near its 52-week low, despite a promising pipeline and a much higher price target, highlights the disconnect between sentiment and reality. For AC Immune, bridging this gap will require not just strong clinical results, but also making those results impossible for the market to ignore.

Key Catalysts and Risks Ahead

The investment case for AC Immune centers on a handful of high-impact events. The coming months will reveal whether the market’s current lack of attention is a fleeting oversight or a lasting judgment. The most important developments to monitor are those that could finally put AC Immune in the spotlight.

• AD3 Cohort Interim Results (H1 2026): The upcoming data from the Phase 2 ABATE trial for ACI-24 could reinvigorate the company’s narrative and attract new capital if positive.
• Full 24-Month Parkinson’s Vaccine Data (Q3 2026): The final results from the Phase 2 VacSYn trial for ACI-7104 will be closely watched for confirmation of the vaccine’s long-term benefits. A strong outcome would be the most compelling evidence yet for the company’s approach.

However, the risks are just as significant. The stock remains out of favor, trading near its lowest point in a year. If investor interest stays low, it may signal that the market has already discounted the company’s story, making it difficult for even positive news to drive a turnaround. Financial pressures are mounting as well, with a net loss of CHF 70.45 million in 2025 and a high cash burn rate. Any delays in reaching key milestones could strain the company’s resources, despite management’s projection that current funds will last through the third quarter of 2027.

In summary, AC Immune’s future hinges on a series of binary outcomes. The company could finally capture the market’s attention with breakthrough clinical results, or it could continue to struggle if progress stalls or goes unnoticed. For now, the story remains one of high risk—but also high potential reward.